Home/Pipeline/Elsulfavirine FDCs (w/ NRTI/INSTI)

Elsulfavirine FDCs (w/ NRTI/INSTI)

HIV-1 Infection

BioequivalenceActive

Key Facts

Indication

HIV-1 Infection

Phase

Bioequivalence

Status

Active

Company

Viriom

About Viriom

Viriom is a clinical-stage biotech company advancing a pipeline of antiviral therapies, primarily for HIV, with a mission to ensure broad global access. Its lead asset, Elpida® (elsulfavirine), is an NNRTI approved in Russia and Eurasian markets, with development ongoing for weekly oral and long-acting injectable formulations. The company is also expanding its focus to include treatments for SARS-CoV-2, influenza, Hepatitis B/C, and solid tumors, supported by a leadership team with deep virology and drug development expertise.

View full company profile

Therapeutic Areas

HIV/AIDS Viral Hepatitis Respiratory Viral Infections Oncology

Other HIV-1 Infection Drugs

Drug	Company	Phase	Status
Lenacapavir	Dr. Reddy's Laboratories	Approved	Commercialization in 120 countries via Gilead partnership
EBT-101	Excision BioTherapeutics	Phase 1/2	Active
Elpida® (elsulfavirine) Daily Oral	Viriom	Approved	Active
Agape® FDC	Viriom	Approved	Active
Depulfavirine Injectable (DPV)	Viriom	Approved	Active
VM3500 LA Injectable	Viriom	Pre-clinical	Active